Laparoscopic sleeve gastrectomy is safe and efficacious for pretransplant candidates Background Morbid obesity is a relative contraindication for organ transplant because it is associated with higher postoperative morbidity and mortality. T... Matthew Y.C. Lin and M. Mehdi Tavakol and Ankit Sarin...
This is a summary of important information that you need to know about ELIQUIS. Keep this document in a safe place, so you can refer to it before and during your treatment.Look out for the following signs as you read: Do not stop taking ELIQUIS without talking to the doctor who ...
it caused dangerous bleeding in patients who were suffering from acute coronary syndrome and who were receiving antiplatelet therapy in addition to apixaban. Studies were halted for these patients in November of 2010, though the medication is still considered to be safe for other groups of patients...
【题目】Important facts about ELIQUIS®(apiraban(apixaba)aletsT his is a summary of important information that you need to know about ELIQUIS .Keep this document in a safe place, so youcan refer to it before and during your treatment.Talk to yourCall a healthcareHelpfu informationhealth...
Apixaban is efficacious and safe in patients with atrial fibrillation using concomitant amiodarone: an analysis from the ARISTOTLE trial. J Am Coll Cardio 2013;1:E317. http://dx.doi.org/10.1016/S0735-1097(13) 60317-4Flaker GC, Hohnloser S, Wojdyla D, Hylek E, Garcia D, Sullivan R, ...
6.Eliquis.apixaban)tabetsImportant facts about ELIQUIS(apixaban)This is a summary of important information that you need to know about ELIQUIS. Keepthis document in a safe place, so you can refer to it before and during your treatment.Look out for theTalk to yourCall a healthcareHelpful info...
(B)apixaban)tabletsImportant facts about ELIQUIS(apixaban)This is a summary of important information that you need to know about ELIQUIS. Keep thisdocument in a safe place, so you can refer to it before and during your treatment.Look out for the followingTalk to yourCall a healthcareHelpfu ...
In ARISTOTLE, patients with atrial fibrillation and ≥2 dose-reduction criteria [age ≥80 years, weight ≤60 kg, and creatinine ≥1.5 mg/dL (133 μmol/L)] were randomized to apixaban 2.5 mg twice daily (b.i.d) or warfarin. PURPOSE. To determine whether the apixaban dose adjustment in ...
Apixaban is approved for VTE prophylaxis. This study seeks to ascertain the risk of VTE and bleeding complications in patients undergoing primary THA and TKA receiving apixaban for postoperative VTE prophylaxis for one of the following indications: high risk for VTE, previously on apixaban, and ...
P4752Apixaban 2.5 mg twice daily is effective and safe for patients with atrial fibrillation and combinations of advanced age, low body weight, and elevated creatinine: insights from ARISTOTLEOral AnticoagulationBACKGROUND. In ARISTOTLE, patients wit...